Article
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
PloS one - 1 Jan 2020
Soldi Raffaella, Ghosh Halder Tithi, Weston Alexis, Thode Trason, Drenner Kevin, Lewis Rhonda, Kaadige Mohan R, Srivastava Shreyesi, Daniel Ampanattu Sherin, Rodriguez Del Villar Ryan, Lang Jessica, Vankayalapati Hariprasad, Weissman Bernard, Trent Jeffrey M, Hendricks William P D, Sharma Sunil
Abstract excerpt
Mutations of the SWI/SNF chromatin remodeling complex occur in 20% of all human cancers, including ovarian cancer. Approximately half of ovarian clear cell carcinomas (OCCC) carry mutations in the SWI/SNF subunit ARID1A, while small cell carcinoma of the ovary hypercalcemic type (SCCOHT) presents with inactivating mutations of the SWI/SNF ATPase SMARCA4 alongside epigenetic silencing of the ATPase SMARCA2. Loss...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
